摘要
目的探究在首发精神分裂症患者的治疗中,氨磺必利与利培酮治疗的临床效果极其安全性。方法选取2013年5月~2016年5月在我院进行治疗的首发精神分裂患者58例,将患者按照不同治疗药物分为对照组（29例,采用利培酮进行治疗）和研究组（29例,采用氨磺必利治疗）,比较两组患者的治疗效果及其安全性。结果与对照组患者相比,研究的治疗效果明显较佳,治疗之后,研究组的PANSS（阴性与阳性综合征量表）评分、CDSS（卡尔加精神分裂抑郁量表）评分以及TESS（不良反应症状量表）评分明显低于对照组,两组PANSS评分、CDSS评分减分值差异较大,两组患者之间数据存在统计学意义（P〈0.05）。结论采用氨磺必利治疗首发精神分裂症的临床效果较佳,且安全性较高。
Objective To explore the clinical efficacy and safety of amisulpride and risperidone in treatment of schizophrenia. Methods 58 cases of patients with schizophrenia cured in our hospital from May 2013 to May 2016 were selected as the study objects. According to the different therapeutic drugs, they were divided into control group（29 cases, treated with risperidone）and study group（29 cases, treated with amisulpride）. Clinical efficacy and safety of the two groups were compared. Results Compared with the control group, the treatment effect of study group was better. After treatment, the scores of PANSS（positive and Negative Syndrome Scale）, CDSS（Carle plus Depression Scale） score and TESS（adverse reaction symptom scale） score in the study group were significantly lower than those in the control group. The PANSS score, CDSS score differences of the two groups were large, and there was statistical significance between the two groups（P〈0.05）. Conclusion The clinical efficacy of amisulpride and risperidone in treatment of schizophrenia is good. Its safety is high.
出处
《中国医药科学》
2016年第21期106-108,共3页
China Medicine And Pharmacy
